Amneal launches generic Zytiga in new dosage strength
The Food and Drug Administration has given its blessing to Amneal for additional strength of 500 mg to its abiraterone acetate tablets, 250 mg. This product is used in combination with Prednisone.
It is the generic of Janssen’s Zytiga for the treatment of metastatic prostate cancer.
Amneal immediately initiated commercialization activities upon approval of the additional 500 mg strength.
Abiraterone tablets, 500 mg, had a market value of $413 million for the 12 months ended November 2020, according to IQVIA.